Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ENO1 | P06733 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9846466 | 0.90 | GAA (0.34) | CCR2ADRA2ANISCHPOLBGAA | |
| SCHEMBL9738795 | 0.81 | TSHR (0.34) | CCR2POLBGAATSHR | |
| SCHEMBL13051347 | 0.74 | ADRA2A (0.35) | ADRA2ANISCHGAAENO1TSHR | |
| SCHEMBL9201441 | 0.71 | ENO1 (0.44) | CCR2HTTL3MBTL1POLBENO1 | |
| SCHEMBL19395640 | 0.70 | ADRA2A (0.33) | ADRA2ANISCHHSD17B10GAAENO1 | |
| SCHEMBL5210529 | 0.70 | MMP1 (0.38) | CCR2HTTHSD17B10L3MBTL1MMP1 | |
| SCHEMBL5065199 | 0.68 | TSHR (0.34) | ADRA2ANISCHTSHRMMP1 | |
| SCHEMBL5986600 | 0.68 | HTT (0.37) | CCR2HTTHSD17B10L3MBTL1POLB | |
| SCHEMBL1243842 | 0.66 | TSHR (0.37) | TSHRATMMMP1 | |
| SCHEMBL923787 | 0.66 | KDM4E (0.34) | ADRA2ANISCHHSD17B10TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753745-A2 | PYRAZINYLMETHYL LACTAM DERIVATIVES | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20050282816-A1 | Pyrazinylmethyl lactam derivatives | PFIZER INC | 2005-12-22 | — | — | US | disclosed |
| WO-2005113535-A2 | PYRAZINYLMETHYL LACTAM DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282816-A1 | Pyrazinylmethyl lactam derivatives | HTR1A, HTR1D, HTR1B | CCR2 606/4885HTT 3138/4885ADRA2A 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.